Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.

Promising Phase 2 Results for Rezatapopt in Solid Tumors

PMV Pharma’s phase 2 PYNNACLE trial has shown encouraging interim results for rezatapopt monotherapy in patients with advanced solid tumours carrying the TP53 Y220C mutation. The trial reported a 33% overall response rate (ORR) among 97 evaluable patients across eight tumour types, with ovarian cancer patients exhibiting the strongest response at a 43% ORR. Notably, endometrial cancer showed a 60% ORR, while lung and breast cancer cohorts had OR…

Rezatapopt shows promise in phase 2 trial for TP53 Y220C solid tumours

Early data reveals strong response rates in ovarian cancer cohort